96 related articles for article (PubMed ID: 11859908)
1. Economic comparison of oral triptans for management of acute migraine: implications for managed care.
Reeder CE; Steadman S; Goldfarb SD
Am J Manag Care; 2002 Feb; 8(3 Suppl):S80-4. PubMed ID: 11859908
[TBL] [Abstract][Full Text] [Related]
2. Health outcomes evaluations: estimating the impact of almotriptan in managed care settings.
Mayo KW; Osterhaus JT
Am J Manag Care; 2002 Feb; 8(3 Suppl):S85-93. PubMed ID: 11859909
[TBL] [Abstract][Full Text] [Related]
3. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project).
Cutrer FM; Goadsby PJ; Ferrari MD; Lipton RB; Dodick DW; McCrory D; Williams P
Clin Ther; 2004 Sep; 26(9):1533-45. PubMed ID: 15531016
[TBL] [Abstract][Full Text] [Related]
4. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P
Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
[TBL] [Abstract][Full Text] [Related]
5. Almotriptan: meeting today's needs in acute migraine treatment.
Láinez MJ
Expert Rev Neurother; 2007 Dec; 7(12):1659-73. PubMed ID: 18052762
[TBL] [Abstract][Full Text] [Related]
6. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.
Gori S; Morelli N; Acuto G; Caiola F; Iudice A; Murri L
Minerva Med; 2006 Dec; 97(6):467-77. PubMed ID: 17213783
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
[TBL] [Abstract][Full Text] [Related]
8. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms.
Mannix LK; Adelman JU; Goldfarb SD; Von S; Kozma CM
Am J Manag Care; 2002 Feb; 8(3 Suppl):S94-101. PubMed ID: 11859910
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials.
Belsey JD
Curr Med Res Opin; 2004 May; 20(5):659-69. PubMed ID: 15140331
[TBL] [Abstract][Full Text] [Related]
10. Advances in migraine management: implications for managed care organizations.
Dodick DW; Lipsy RJ
Manag Care; 2004 May; 13(5):45-51. PubMed ID: 15181689
[TBL] [Abstract][Full Text] [Related]
11. Oral almotriptan: practical uses in the acute treatment of migraine.
Dowson AJ
Expert Rev Neurother; 2004 May; 4(3):339-48. PubMed ID: 15853532
[TBL] [Abstract][Full Text] [Related]
12. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls.
Loder E; Goldstein R; Biondi D
Cephalalgia; 2005 Feb; 25(2):124-31. PubMed ID: 15658949
[TBL] [Abstract][Full Text] [Related]
13. [Management costs of chest and CNS-related adverse events associated with the treatment of acute migraine attacks with oral triptans].
Slof J; Badia X; Lainez-Andres JM; Galvan J; Heras J
Neurologia; 2005; 20(6):290-8. PubMed ID: 16007512
[TBL] [Abstract][Full Text] [Related]
14. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.
Kelman L; Von Seggern RL
Am J Ther; 2006; 13(5):411-7. PubMed ID: 16988536
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic issues associated with switching between triptans in clinical practice.
Dowson AJ; Fuat A; Gruffydd-Jones K
Curr Med Res Opin; 2005 Mar; 21(3):375-9. PubMed ID: 15811206
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
17. Review of clinical trials using early acute intervention with oral triptans for migraine management.
Dowson AJ; Mathew NT; Pascual J
Int J Clin Pract; 2006 Jun; 60(6):698-706. PubMed ID: 16805756
[TBL] [Abstract][Full Text] [Related]
18. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
19. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms.
Dodick DW; Martin V
Cephalalgia; 2004 Jun; 24(6):417-24. PubMed ID: 15154851
[TBL] [Abstract][Full Text] [Related]
20. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
Winner P; Landy S; Richardson M; Ames M
Clin Ther; 2005 Nov; 27(11):1785-94. PubMed ID: 16368449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
